<DOC>
	<DOCNO>NCT02672852</DOCNO>
	<brief_summary>This confirmatory , multicentre , randomize , double-blind , placebo control , 104 week study 88 week treatment period 16 week follow-up period evaluate efficacy safety BI 655066 / ABBV-066 ( risankizumab ) support Registration treatment moderate severe chronic plaque psoriasis adult patient . This study also look maintenance response follow randomly withdraw treatment patient respond treatment week 28 , well response re-treatment patient relapse . This study also assess PK emergence anti-drug antibody well influence study treatment disease specific marker . In subset psoriasis patient concomitant psoriatic arthritis , sign symptom psoriatic arthritis evaluate assess improvement .</brief_summary>
	<brief_title>BI 655066 / ABBV-066 ( Risankizumab ) Moderate Severe Plaque Psoriasis With Randomized Withdrawal Re-treatment</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Inclusion criterion : Male female patient . Woman childbearing potential must ready willing use highly effective method birth control per ICH M3 ( R2 ) result low failure rate le 1 percent per year use consistently correctly . Age &gt; =18 year screen Have diagnosis chronic plaque psoriasis ( without psoriatic arthritis ) least 6 month first administration study drug . Duration diagnosis may report patient . Have stable moderate severe chronic plaque psoriasis without psoriatic arthritis Screening Baseline ( Randomization ) ; Have involve body surface area ( BSA ) &gt; = 10 % Have Psoriasis Area Severity Index ( PASI ) &gt; = 12 Have static Physician Global Assessment ( sPGA ) score &gt; = 3 . Must candidate systemic therapy phototherapy psoriasis treatment , assess investigator Signed date write informed consent prior admission study performance study procedure accordance GCP local legislation Exclusion criterion : Patients nonplaque form psoriasis ( include guttate , erythrodermic , pustular ) ; current druginduced psoriasis ( include new onset psoriasis exacerbation psoriasis beta blocker , calcium channel blocker , lithium ) ; active ongoing inflammatory disease psoriasis psoriatic arthritis might confound trial evaluation accord investigator judgment . Previous exposure ABBV066 Currently enrol another investigational study le 30 day ( screen ) since complete another investigational study Use restrict medication note drug consider likely interfere safe conduct study . Major surgery perform within 12 week prior randomization plan within 12 month screen ( e.g . hip replacement , removal aneurysm , stomach ligation , ) . Known chronic relevant acute infection active tuberculosis , HIV , viral hepatitis Any document active suspected malignancy history malignancy within 5 year prior screen , except appropriately treat basal cell carcinoma squamous cell carcinoma skin situ carcinoma uterine cervix Evidence current previous disease ( include chronic alcohol drug abuse ) , medical condition psoriasis , surgical procedure ( i.e. , organ transplant ) , medical examination finding ( include vital sign ECG ) , laboratory value screen visit outside reference range opinion Investigator , clinically significant would make study participant unable adhere protocol complete trial , compromise safety patient , compromise quality data . History allergy/hypersensitivity systemically administer biologic agent excipients Women pregnant , nursing , plan become pregnant trial Previous enrolment trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ABBV-066</keyword>
	<keyword>BI 655066</keyword>
	<keyword>risankizumab</keyword>
</DOC>